4.5 Review

The Use of Physiologically Based Pharmacokinetic Analyses-in Biopharmaceutics Applications -Regulatory and Industry Perspectives

Journal

PHARMACEUTICAL RESEARCH
Volume 39, Issue 8, Pages 1681-1700

Publisher

SPRINGER/PLENUM PUBLISHERS
DOI: 10.1007/s11095-022-03280-4

Keywords

biopharmaceutics; clinically relevant dissolution; critical bioavailability attributes; critical quality attributes; PBBM; PBPK

Ask authors/readers for more resources

The use of physiologically based biopharmaceutics modeling (PBBM) to support drug product quality attributes is an evolving field with growing interest. Establishing an in vitro-in vivo link is crucial for achieving patient centric quality standards. While PBBM offers advantages, there are challenges that require further improvements. Collaboration between regulatory, industry, and academic fields can advance the field and deliver on the promises of PBBM in establishing patient centric quality standards.
The use of physiologically based pharmacokinetic (PBPK) modeling to support the drug product quality attributes, also known as physiologically based biopharmaceutics modeling (PBBM) is an evolving field and the interest in using PBBM is increasing. The US-FDA has emphasized on the use of patient centric quality standards and clinically relevant drug product specifications over the years. Establishing an in vitroin vivo link is an important step towards achieving the goal of patient centric quality standard. Such a link can aid in constructing a bioequivalence safe space and establishing clinically relevant drug product specifications. PBBM is an important tool to construct a safe space which can be used during the drug product development and lifecycle management. There are several advantages of using the PBBM approach, though there are also a few challenges, both with in vitro methods and in vivo understanding of drug absorption and disposition, that preclude using this approach and therefore further improvements are needed. In this review we have provided an overview of experience gained so far and the current perspective from regulatory and industry point of view. Collaboration between scientists from regulatory, industry and academic fields can further help to advance this field and deliver on promises that PBBM can offer towards establishing patient centric quality standards.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available